Nitroglycerin

PDE-5 inhibitor that potentiates hypotensive effects of nitroglycerin. Contraindicated with nitroglycerin.

Nitroglycerin markedly decreases first-pass metabolism of ergotamine, increasing bioavailability. Ergotamine can precipitate angina pectoris. Avoid concomitant use.

Soluble guanylate cyclase stimulators cause severe hypotension when used with nitroglycerin. Concomitant use is contraindicated.

Concomitant use of nitroglycerin with phosphodiesterase inhibitors in any form is contraindicated.

Concomitant use of nitroglycerin with riociguat, a soluble guanylate cyclase stimulator, is contraindicated.

PDE-5 inhibitor that potentiates hypotensive effects of nitroglycerin. Contraindicated with nitroglycerin.

Concomitant use is contraindicated; PDE-5 inhibitors potentiate hypotensive effects of organic nitrates.

sGC stimulators are contraindicated with nitroglycerin. Concomitant use can cause severe hypotension.

PDE-5 inhibitor that potentiates hypotensive effects of nitroglycerin. Contraindicated with nitroglycerin.

PDE-5 inhibitor that potentiates hypotensive effects of nitroglycerin. Contraindicated with nitroglycerin.

Concomitant use of vardenafil hydrochloride and nitroglycerin is contraindicated. Vardenafil potentiates the blood pressure lowering effects.

Concomitant use may cause hypotension.

Intravenous nitroglycerin decreases the thrombolytic effect of alteplase; caution advised with sublingual nitroglycerin during alteplase therapy.

Concomitant use causes greater decreases in blood pressure compared to apomorphine alone, with risk of hypotension, myocardial infarction, falls, and injuries.

Increased risk of methemoglobinemia when concurrently exposed to articaine.

Increased risk of developing methemoglobinemia when concurrently exposed to this nitrate.

Increased risk of methemoglobinemia when concurrently exposed to this nitrate oxidizing agent with local anesthetics.

Increased risk of methemoglobinemia when local anesthetics are used concomitantly with nitrates/nitrites.

Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.

Marked symptomatic orthostatic hypotension reported when combined with organic nitrates. Dose adjustments of either class may be necessary.

Induces methemoglobinemia; concomitant use may increase risk for developing methemoglobinemia.

Concomitant use may increase risk of developing methemoglobinemia. Monitor closely.

Increased risk of methemoglobinemia when used with ropivacaine.

Oral nitroglycerin markedly decreases first-pass metabolism and increases bioavailability of dihydroergotamine; monitor for ergotism symptoms.

Intravenous nitroglycerin interferes with the anticoagulant effect of heparin in some patients. Concomitant heparin therapy should be guided by frequent measurement of activated partial thromboplastin time.

Intravenous nitroglycerin may decrease partial thromboplastin time with rebound effect upon discontinuation. Careful monitoring and heparin dose adjustment recommended.

Increased risk of methemoglobinemia when used concurrently with lidocaine.

Nitrate that may cause methemoglobinemia when used concomitantly with lidocaine patch 5%.

Nitrate drug that increases risk of methemoglobinemia when used concurrently with lidocaine and capsaicin patch.

Nitrate/nitrite; increased risk of methemoglobinemia when concurrently exposed.

Increased risk of methemoglobinemia when used concurrently with lidocaine hydrochloride.

Associated with methemoglobinemia risk when concurrent exposure occurs with local anesthetics.

Increased risk of methemoglobinemia when local anesthetic is concurrently exposed to nitrates/nitrites.

Concurrent exposure increases risk of methemoglobinemia in patients administered local anesthetics.

Increased risk of methemoglobinemia when concurrently exposed; nitrates/nitrites may cause methemoglobinemia when used with local anesthetics.

Increased risk of methemoglobinemia when used with lidocaine.

Increased risk of methemoglobinemia when lidocaine is concurrently exposed to nitrates.

Increased risk of methemoglobinemia when local anesthetics are concurrently exposed to nitrates.

Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites.

Concurrent exposure increases risk of methemoglobinemia in patients administered mepivacaine.

May increase the risk of developing methemoglobinemia when used with nitric oxide.

Beta-blockers blunt reflex tachycardia but not hypotensive effects of nitroglycerin, potentially causing additional hypotension in angina patients.

Increased risk of methemoglobinemia when penicillin is concurrently administered with nitroglycerin (a nitrate).

Increased risk of methemoglobinemia when prilocaine is concurrently exposed to nitroglycerin.

Increased risk of methemoglobinemia when used concurrently with prilocaine.

Increased risk of developing methemoglobinemia when concurrently exposed to nitroglycerin.

Increased risk of methemoglobinemia when concurrently exposed.

Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.

Increased risk of methemoglobinemia when used with Trubrexa Transdermal Patch.

May increase risk of developing methemoglobinemia when used with ULSPIRA.

Increases nitroglycerin maximum concentrations by up to 67% and AUC by 73%, potentially enhancing pharmacological effects. Monitor closely.

Tricyclic antidepressant may cause dry mouth and diminished salivary secretions, making sublingual nitroglycerin dissolution difficult.

May increase risk of methemoglobinemia when concurrently exposed with bupivacaine.

Increased risk of methemoglobinemia when concurrently exposed.

Increased risk of developing methemoglobinemia when concurrently exposed.

Data on concomitant use with captopril for heart failure are not available. Should be discontinued before starting captopril if possible; if resumed, administer cautiously at lower dosage.

Concomitant use may cause excessive vasodilation. Should be discontinued before starting captopril; if resumed, administer cautiously at lower dosage.

Tricyclic antidepressant may cause dry mouth and diminished salivary secretions, making sublingual nitroglycerin dissolution difficult.

Tricyclic antidepressant may cause dry mouth and diminished salivary secretions, making sublingual nitroglycerin dissolution difficult.

Labetalol blunts reflex tachycardia from nitroglycerin and may produce additional antihypertensive effects when used concomitantly in angina patients.

Labetalol blunts reflex tachycardia from nitroglycerin without preventing hypotensive effect; additional antihypertensive effects may occur.

Nitrate/nitrite that increases risk of methemoglobinemia when used concomitantly with lidocaine and tetracaine.

Use of long-acting nitrates may result in a decrease in therapeutic effect of sublingual nitroglycerin.

Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites with bupivacaine.

Antianginal drug; methylergonovine produces vasoconstriction and may reduce the effect of glyceryl trinitrate.

Methylergonovine produces vasoconstriction and can reduce the effect of glyceryl trinitrate and other antianginal drugs.

Isradipine has been safely coadministered with nitroglycerin with no reported adverse effects.